Max Kates

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10444832/publications.pdf

Version: 2024-02-01

109 papers	2,584 citations	172457 29 h-index	223800 46 g-index
110 all docs	110 docs citations	110 times ranked	3627 citing authors

#	Article	IF	Citations
1	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 9.e1-9.e7.	1.6	9
2	Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival. Journal of Urology, 2022, 207, 77-85.	0.4	9
3	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. Journal of Urology, 2022, 207, 61-69.	0.4	9
4	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-GuÃ©rin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. Journal of Urology, 2022, 207, 534-540.	0.4	4
5	A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-GuÃ©rin-exposed Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2022, 81, 138-142.	1.9	12
6	<scp>BCG</scp> invokes superior <scp>STING</scp>â€mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. Journal of Pathology, 2022, 256, 223-234.	4.5	9
7	Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. Clinical Genitourinary Cancer, 2022, 20, 60-68.	1.9	6
8	Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
9	Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. Nature Communications, 2022, 13, 878.	12.8	33
10	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e13-195.e18.	1.6	6
11	Indeterminate atypia in urinary tract cytology: Does it really matter?. Diagnostic Cytopathology, 2022, 50, 176-183.	1.0	5
12	Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. Journal of Urology, 2022, 208, 821-829.	0.4	4
13	Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug Delivery and Translational Research, 2021, 11, 2085-2095.	5.8	3
14	Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. European Urology Oncology, 2021, 4, 117-120.	5.4	5
15	Dynamic Contrast Enhanced-MR CEST Urography: An Emerging Tool in the Diagnosis and Management of Upper Urinary Tract Obstruction. Tomography, 2021, 7, 80-94.	1.8	8
16	Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?. European Urology, 2021, 79, 619-620.	1.9	0
17	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. Cell Reports Medicine, 2021, 2, 100382.	6.5	17
18	Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.. Journal of Urology, 2021, , 101097JU0000000000002306.	0.4	0

#	Article	IF	Citations
19	Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 127-135.	1.2	5
20	Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor. World Journal of Urology, 2020, 38, 389-395.	2.2	3
21	Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 5.e9-5.e16.	1.6	11
22	An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 40.e17-40.e24.	1.6	13
23	Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. European Urology Focus, 2020, 6, 3-6.	3.1	6
24	Evaluation of Incisional Negative Pressure Wound Therapy in the Prevention of Surgical Site Occurrences After Radical Cystectomy: A New Addition to Enhanced Recovery After Surgery Protocol. European Urology Focus, 2020, 6, 698-703.	3.1	7
25	Adaptive Immune Resistance to Intravesical BCG in Nonâ€“Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	7.0	98
26	Plastic exposure and urological malignancies â€” an emerging field. Nature Reviews Urology, 2020, 17, 653-654.	3.8	2
27	Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2020, 203, 902-909.	0.4	90
28	Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.. Journal of Clinical Oncology, 2020, 38, 525-525.	1.6	0
29	Development and validation of a NanoString BASE47 bladder cancer gene classifier. PLoS ONE, 2020, 15, e0243935.	2.5	9
30	A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models. Journal of Urology, 2020, 203, 546-553.	0.4	3
31	Reply by Authors. Journal of Urology, 2020, 203, 552-553.	0.4	0
32	Predictive biomarkers for drug response in bladder cancer. International Journal of Urology, 2019, 26, 1044-1053.	1.0	50
33	Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nature Reviews Urology, 2019, 16, 599-612.	3.8	39
34	Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology. World Journal of Urology, 2019, 37, 2051-2058.	2.2	12
35	Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue lightâ€“positive lesions diagnosed as atypical. Human Pathology, 2019, 90, 1-7.	2.0	6
36	Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 2683-2689.	2.2	8

#	Article	IF	Citations
37	Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines. Oncology Letters, 2019, 18, 4923-4929.	1.8	7
38	Validation of an artificial intelligence algorithm applied to a metabolic substrate analysis of urine for detection of urothelial cancer.. Journal of Clinical Oncology, 2019, 37, e16008-e16008.	1.6	0
39	Editorial Comment. Journal of Urology, 2019, 202, 769-769.	0.4	0
40	Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. Journal of Urology, 2018, 200, 68-73.	0.4	46
41	Arsenic promotes the <scp>COX2/PGE2â€“SOX2</scp> axis to increase the malignant stemness properties of urothelial cells. International Journal of Cancer, 2018, 143, 113-126.	5.1	21
42	Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. Urology, 2018, 115, 82-86.	1.0	16
43	Ex vivo culture of tumor cells from N-methyl-N-nitrosoureaâ€“induced bladder cancer in rats: Development of organoids and an immortalized cell line. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 160.e23-160.e32.	1.6	13
44	Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. Annals of Nuclear Medicine, 2018, 32, 69-74.	2.2	28
45	Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery Era. Urology, 2018, 111, 86-91.	1.0	52
46	Three-dimensional organoid culture reveals involvement of Wnt/Î²-catenin pathway in proliferation of bladder cancer cells. Oncotarget, 2018, 9, 11060-11070.	1.8	46
47	CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. British Journal of Cancer, 2018, 119, 961-970.	6.4	27
48	Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?. BJU International, 2018, 122, 1016-1024.	2.5	10
49	Editorial Comment. Journal of Urology, 2018, 200, 1011-1012.	0.4	0
50	PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. European Urology, 2017, 71, 145-146.	1.9	40
51	Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 38.e17-38.e24.	1.6	8
52	Immunotherapy for Prostate Cancerâ€”Why Now?. Urology Practice, 2017, 4, 329-334.	0.5	1
53	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology, 2017, 102, 148-158.	1.0	12
54	M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury. Journal of Sexual Medicine, 2017, 14, 187-195.	0.6	23

#	Article	IF	Citations
55	Evaluation of genderâ€based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database. BJU International, 2017, 120, 377-386.	2.5	7
56	Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database. Journal of Sexual Medicine, 2017, 14, 810-817.	0.6	10
57	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunology Research, 2017, 5, 594-603.	3.4	54
58	Author Reply. Urology, 2017, 102, 158.	1.0	0
59	Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors. Journal of Sexual Medicine, 2017, 14, 1059-1065.	0.6	7
60	Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2017, 23, 6592-6601.	7.0	43
61	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer, 2017, 3, 191-199.	0.4	4
62	Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample. Journal of Urology, 2017, 197, 235-240.	0.4	39
63	Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. Journal of Urology, 2017, 197, 296-301.	0.4	39
64	Ex Vivo Model of Human Penile Transplantation and Rejection: Implications for Erectile Tissue Physiology. European Urology, 2017, 71, 584-593.	1.9	21
65	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e17-34.e25.	1.6	21
66	Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2017, 3, 293-303.	0.4	60
67	Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC.. Journal of Clinical Oncology, 2017, 35, 4546-4546.	1.6	4
68	Examining gemcitabine and docetaxel for recurrent NMIBC.. Journal of Clinical Oncology, 2017, 35, 322-322.	1.6	0
69	Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis.. Journal of Clinical Oncology, 2017, 35, 4588-4588.	1.6	0
70	2542. Journal of Clinical and Translational Science, 2017, 1, 83-83.	0.6	0
71	Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Canadian Urological Association Journal, 2016, 10, 389.	0.6	17
72	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology, 2016, 5, e1134412.	4.6	135

#	Article	IF	Citations
73	Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 532.e1-532.e6.	1.6	13
74	Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. populationâ€“based analysis (2004â€“2012). Urologic Oncology: Seminars and Original Investigations, 2016, 34, 531.e15-531.e24.	1.6	27
75	Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference. Bladder Cancer, 2016, 2, 225-234.	0.4	19
76	Prostate-specific Antigen Mass Densityâ€"A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. Urology, 2016, 90, 141-147.	1.0	11
77	Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e1-256.e6.	1.6	86
78	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. Journal of Urology, 2016, 195, 337-342.	0.4	43
79	Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology, 2016, 34, 49-55.	2.2	15
80	Effect of chemotherapy and/or TURBT on pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2016, 34, 395-395.	1.6	0
81	Use of regenerative tissue for urinary diversion. Current Opinion in Urology, 2015, 25, 578-585.	1.8	12
82	Indications for intervention during active surveillance of prostate cancer: a comparison of the <scp>J</scp>ohns <scp>H</scp>opkins and <scp>P</scp>rostate <scp>C</scp>ancer <scp>R</scp>esearch <scp>I</scp>nternational <scp>A</scp>ctive <scp>S</scp>urveillance (<scp>PRIAS</scp>) protocols. BJU International, 2015, 115, 216-222.	2.5	25
83	Tissue-Engineered Urinary Conduits. Current Urology Reports, 2015, 16, 8.	2.2	27
84	Reply. Urology, 2015, 86, 78-79.	1.0	0
85	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 204.e1-204.e7.	1.6	34
86	Sickle Cell Disease in Priapism: Disparity in Care?. Urology, 2015, 86, 72-79.	1.0	14
87	Morbidity of Urologic Surgical Procedures: An Analysis of Rates, Risk Factors, and Outcomes. Urology, 2015, 85, 552-560.	1.0	83
88	Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 426.e1-426.e12.	1.6	78
89	Balancing cardiovascular (CV) and cancer death among patients with small renal masses: modification by CV risk. BJU International, 2015, 115, 58-64.	2.5	31
90	The Financial Impact of Robotic Technology for Partial and Radical Nephrectomy. Journal of Endourology, 2015, 29, 317-322.	2.1	19

#	Article	IF	Citations
91	Comorbidities and causes of death in the management of localized <scp>T</scp>1a kidney cancer. International Journal of Urology, 2014, 21, 1086-1092.	1.0	42
92	Survival After Diagnosis of Localized T1a Kidney Cancer: Current Population-based Practice of Surgery and Nonsurgical Management. Urology, 2014, 83, 126-133.	1.0	52
93	Stones in the Elderly. Current Geriatrics Reports, 2014, 3, 14-18.	1.1	6
94	Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: A comorbidity-controlled competing-risks model. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 576-583.	1.6	31
95	In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 53.e9-53.e14.	1.6	15
96	Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-GuÃ©rin Treatment Failure. Journal of Urology, 2014, 192, 1633-1638.	0.4	74
97	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal of Urology, 2013, 31, 1535-1539.	2.2	61
98	â€œNever Eventsâ€ Centers for Medicare and Medicaid Services Complications After Radical Cystectomy. Urology, 2013, 81, 527-532.	1.0	19
99	The effect of race and gender on the surgical management of the small renal mass. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1794-1799.	1.6	29
100	Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 2693-2699.	1.5	37
101	Predictors of locally advanced and metastatic disease in patients with small renal masses. BJU International, 2012, 109, 1463-1467.	2.5	23
102	Secondary bladder cancer after upper tract urothelial carcinoma in the US population. BJU International, 2012, 110, 1325-1329.	2.5	18
103	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. Journal of Clinical Oncology, 2012, 30, 4623-4623.	1.6	1
104	Persistent Overuse of Radical Nephrectomy in the Elderly. Urology, 2011, 78, 555-559.	1.0	17
105	Increased Risk of Overall and Cardiovascular Mortality After Radical Nephrectomy for Renal Cell Carcinoma 2 cm or Less. Journal of Urology, 2011, 186, 1247-1253.	0.4	68
106	Renal functional outcomes after surgery for renal cortical tumors. Current Opinion in Urology, 2011, 21, 351-355.	1.8	10
107	Survival Following Lobectomy and Limited Resection for the Treatment of Stage I Non-small Cell Lung Cancer â‰¤ 1 cm in Size. Chest, 2011, 139, 491-496.	0.8	182
108	Validation of a Model to Predict Perioperative Mortality from Lung Cancer Resection in the Elderly. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 390-395.	5.6	46

#	Article	IF	Citations
109	Prediction of Perioperative Mortality after Lung Cancer Resection in the Elderly. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 794-795.	5.6	0